Cannabis: Regulation and public health

More and more countries are adopting a new stance toward the cannabis industry. Greater comprehension and understanding of the topic is evidenced on the part of the authorities. Modifications in current regulations as well as flexibility in public health care policies reflect the commitment and concern for those patients for whom the consumption of medicinal cannabis is indispensable as part of their treatment.

The authorization to commercialize medicinal cannabis products represents an encouraging future for pharmaceutical corporations in the world. This represents the emergence of new markets with a high demand and, at the same time, facing the challenge that medications cease to comply with the Buenas Prácticas de Manufactura (BPM) before reaching the population.

EXILBY: The first authorized cannabis analgesic in the world

Exilby recibió de parte del Instituto Federal Alemán de Medicamentos y Dispositivos Médicos la aprobación para su venta en Alemania. Exilby is a tincture with an analgesic effect manufactured by the laboratory Vertanical. Vertanical.

The medication was approved for the treatment of chronic back pain and lumbar pain as a neuropathic or radicular component in adults. It is expected to be on sale in the German market in the fall of 2026.

According to statements of its creator, Clemens Fischer: “We are (Vertanical) the first company worldwide that has repeatedly demonstrated that our drug, our extract, works better than the placebo and better than opioids.”

Where can I buy Exilby?

For the moment, the authorized sale of Exilby is in Germany and Austria.

Según los CDC de Estados Unidos (Centros para el Control y la Prevención de Enfermedades) el 24% de la población adulta sufre dolor crónico.

En mayo, la FDA (Administración de Alimentos y Medicamentos) otorgó a Vertanical la designación de terapia innovadora para su fármaco en investigación. La compañía tiene previsto iniciar los ensayos clínicos de fase III en Estados Unidos este verano.

Oficialmente el gobierno federal de los Estados Unidos ha cambiado su postura hacia el cannabis. En el mes de abril, el Departamento de Justicia de los Estados Unidos reclasificó a la marihuana medicinal y la incorporó en una lista de drogas de nivel III, menos restrictivas como el caso de los esteroides, Ketamina y Tylenol con Codeína.

If you liked this note, save the information and share it with a colleague who it may serve. OMC Abogados & Consultores finds itself at your complete disposal if you have any query regarding cannabis regulation in Peru, just enter the link: https://omcabogados.com.pe/en/legal-consultation-trademark-patent-in-peru-and-latin-america/